China Independent Clinical Laboratory Industry Report, 2011-2012
  • Aug./2012
  • Hard Copy
  • USD $1,500
  • Pages:60
  • Single User License
    (PDF Unprintable)       
  • USD $1,400
  • Code: ZYM033
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,200
  • Hard Copy + Single User License
  • USD $1,700
The independent clinical laboratory industry starts late and is still in its infancy in China, featuring a limited market size of less than RMB2 billion at present which just accounts for 1%-2% of the total revenue of medical diagnosis. Additionally, the independent clinical laboratories in home market can conduct 1,000 or more diagnostic items, while those in a developed country such as the U.S. are capable of carrying out as many as 4,000 diagnostic items. What is worse, China lags far behind developed countries in diagnostic levels, especially in genetic/molecular diagnostics market segment.

Currently, there are roughly 110 independent clinical laboratories in China, but most of them are small sized. Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc. and Gaoxin-Da An (invested by DAAN Gene) are the leading companies in Chinese independent clinical laboratory industry and adopt comprehensive diagnostic service mode on the basis of chain operation, together making up approximately 70% market share. Although with a small portion of market share, Beijing NYMPHAVN Biotechnology, Beijing Adinovo Genetic Technology and Zhiyuan Medical Inspection Institute occupy a certain position in the market by virtue of special featured diagnostic service.

The demand from downstream market and the introduction of favorable policies like encouraging the development of private medical institutions arouse keen interest of foreign companies in Chinese independent clinical laboratory market. A large number of foreign enterprises have tapped into Chinese market through technical cooperation or direct capital injection.

In early 2012, DAAN Gene (002030) and Life Technologies co-founded Life Technologies DaAn Diagnostics and announced the official launch of DNA sequencing molecular diagnostics project.

In February 2012, Centre Testing International Corporation cooperated with Amcare Labs International in establishing Johns Hopkins (China) Medical Laboratories in Shanghai (registered capital of USD10 million and equity ratio of 51:49) to carry out the independent medical testing service.

In March 2012, Kindstar Global (Beijing) Medical Technology secured USD20 million in Series C funding from such investors as KPCB China, WI Harper Group, Baird Capital Partners Asia and Mayo Clinic, of which the latter three companies also participated in the company’s Series B financing of USD11 million in June 2011.

The report revolves around the followings:
  • The access policy, industrial policy, international market environment and so forth of Chinese independent clinical laboratory industry;
  • Status quo, competitive landscape, prospects and dynamics of Chinese independent clinical laboratory industry;
  • The effects of the development of upstream diagnostic reagent and instrument, and downstream medical institutions on Chinese independent clinical laboratory industry;
  • Operation, competitive advantages and prospects of 9 independent clinical laboratories including Kingmed Diagnostics, Zhejiang D.A. Diagnostics, ADICON Clinical Laboratories, Inc., DAAN Gene and Kindstar Global (Beijing) Medical Technology, etc.

1 Profile of Independent Clinical Laboratory
1.1 Definition 
1.2 Industry Chain

2 Overview of China Independent Clinical Laboratory Industry
2.1 Policies
2.1.1 Access Policies
2.1.2 Industry Policies
2.2 Global Market
2.2.1 Status Quo
2.2.2 Model Enterprises
2.3 Current Development
2.4 Competitive Landscape
2.5 Dynamics and Prospects

3 Upstream and Downstream Industry of China Independent Clinical Laboratory
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Product Mix
3.2 Downstream Sector
3.2.1 Huge Market Scale of Chinese Independent Clinical Laboratory
3.2.2 Medical Reform Encourages Rapid Development of Independent Clinical Laboratory in China
3.2.3 Diversified Demand Promotes the Upgrading of Independent Clinical Laboratory Industry in China

4 Key Players in China
4.1 Kingmed Diagnostics Co., Ltd
4.1.1 Profile
4.1.2 Operation and Prospects
4.2 Zhejiang D.A. Diagnostics Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R & D and Investment
4.2.7 Independent Clinical Laboratory Service
4.3 DAAN Gene Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.5 Gross Margin
4.3.6 Independent Clinical Laboratory Service
4.4 Beijing NYMPHAVN Biotechnology Corporation Ltd
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients and Suppliers
4.4.6 R & D and Investment
4.5 ADICON Clinical Laboratories, Inc
4.6 Beijing Deyi Biotechnology Medical Co., Ltd
4.7 Beijing Adinovo Genetic Technology Co., Ltd
4.8 Zhiyuan Medical Inspection Institute Co., Ltd
4.9 Kindstar Global (Beijing) Medical Technology Co., Ltd
Industry Chain of Independent Clinical Laboratory
Comparison of Independent Clinical Laboratory between China and the USA by Undertaker 
Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2011
Market Share of Independent Clinical Laboratory Industry in the U.S. by Diagnostic Item, 2003-2010
Market Share of Medical Diagnostics in the USA by Undertaker, 2010
Revenue and Profit of Quest Diagnostics, 2007-2011
Revenue Structure of Quest Diagnostics by Business, 2011
Major M&As of Quest Diagnostics, 2006-2011
Revenue and Profit of Labcorp, 2007-2011
Revenue Breakdown of Labcorp by Business, 2009-2011
Major M&As of Labcorp, 2007-2011
Top 5 Diagnostic Items of Massachusetts General Hospital and Domestic Third-grade Class-A Hospital
Characteristics and Market Share of Major Independent Clinical Laboratories in China, by the End of 2011
Market Size and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2014E
Market Scale and Growth Rate of In Vitro Diagnostic Reagent in China, 2007-2014E
Structure of In Vitro Diagnostic Reagent in China, 2011
Business Revenue and Diagnostics Revenue of Medical Institutions in China, 2010 
Number of Visits in Hospitals and Basic Medical Institutions, 2008-2011
Number of Public and Non-public Hospitals in China, 2008-2011
Layout of D.A. Diagnostics’ Independent Clinical Laboratory
Revenue and Profit of D.A. Diagnostics, 2008-2012
Revenue Breakdown of D.A. Diagnostics by Business, 2008-2011
Revenue Structure of D.A. Diagnostics by Business, 2008-2011
Revenue Breakdown of D.A. Diagnostics by Region, 2008-2011
Revenue Structure of D.A. Diagnostics by Region, 2008-2011
Gross Margin of D.A. Diagnostics by Business, 2008-2011
D.A. Diagnostics’ Revenue from Top 5 Clients and % of Total Revenue, 2008-2011
Name List and Revenue Contribution of D.A. Diagnostics’ Top 5 Clients, 2009-2011
D.A. Diagnostics’ Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2011
Name List and Procurement Contribution of D.A. Diagnostics’ Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of D.A. Diagnostics, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business, 2008-2011
Revenue and Gross Margin of D.A. Diagnostics’ Independent Diagnostics Business by Product, 2008-2011
Revenue Structure of D.A. Diagnostics’ Independent Diagnostics Business by Client, 2010-2011
Forecast of D.A. Diagnostics’ Revenue by Business, 2011-2014E
Revenue and Profit of DAAN Gene, 2008-2012
Revenue Breakdown of DAAN Gene by Product, 2008-2011
Revenue Structure of DAAN Gene by Region, 2008-2011
Gross Margin of DAAN Gene by Product, 2008-2011
Revenue and Gross Margin Of DAAN Gene’s Independent Diagnostics Business, 2008-2011
Net Assets, Revenue and Net Income of DAAN Gene’s Subsidiaries Engaging in Independent Diagnostics Business, 2011
Revenue and Profit of NYMPHAVN Biotechnology, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Structure of NYMPHAVN Biotechnology by Product, 2009-2011
Revenue Breakdown of NYMPHAVN Biotechnology by Region, 2010-2011
Gross Margin of NYMPHAVN Biotechnology by Product, 2009-2011
NYMPHAVN Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of NYMPHAVN Biotechnology’s Top 5 Clients, 2009-2011
NYMPHAVN Biotechnology’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
Name List and Procurement Contribution of NYMPHAVN Biotechnology’s Top 5 Suppliers, 2009-2011
R&D Costs and % of Total Revenue of NYMPHAVN Biotechnology, 2009-2011
Distribution and Established Date of Adicon’s Independent Clinical Laboratory

China Dental Industry Report, 2014-2018

Oral industry refers to the medical industry chain on the basis of oral medical consumption, mainly covering oral medical apparatus (equipment and consumables) and oral medical services. As reform of ...

China Medical Monitor Industry Report, 2014-2017

With advancement of medical reform, improvement of spending power, and enhancement of health care consciousness, China’s medical monitor industry is gradually expanding. During 2007-2013, the market s...

China Independent Clinical Laboratory Industry Report, 2014-2017

The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there...

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号